Futurology

“While early, these results are highly encouraging after delivering just a single, off-the-shelf administration of VNX-101, which enables the body to produce a CD19/CD3 T-cell–engaging protein,” said Samit Varma, Chief Executive Officer of Vironexis. “These three patients have tried multiple lines of therapy and, sadly, exhausted available treatment options. We believe the depth, consistency, and emerging durability of these responses provide important clinical validation of our in vivo therapeutic proteinplatform, and compelling proof of concept for its potential to transform the body into a meaningful, durable source of highly active cancer therapeutics.”

As ever, caveats apply from such a small sample. However, this is a highly encouraging demonstration of this new approach.

Vironexis Announces Complete and Durable Responses in Relapsed/Refractory ALL Patients Treated with VNX-101